On Tuesday, Sept. 14, Judicial Watch announced that it received records and communications from the U.S. Food and Drug Administration (FDA) involving research—during the Obama administration—in which purchased human fetal organs and tissues were used to experiment on “humanized mice.”

Judicial Watch received 198 pages of records through a March 2019 Freedom of Information Act (FOIA) lawsuit against the U.S. Department of Health and Human Services, of which FDA is a part.

Judicial Watch requested all contracts and related documentation regarding the disbursement of funds, procedures, and communications between the FDA and biotech ABR (Advanced Bioscience Resources) to provide human fetal tissue used in humanized mouse research.

Most of the records disclosed by FOIA are communications and attachments between ABR’s procurement manager, Perrin Larton, and veterinary medical researcher Dr. Kristina Howard of the FDA.

The court reviewing the case found that “there is reason to question” whether the transactions violate federal law prohibiting the sale of fetal organs.

Documents previously uncovered in this lawsuit show that the federal government required that fetal organs purchased be “fresh and never frozen.”

The registrations included an FDA-generated contract with ABR, based on a “requisition” issued on July 27, 2012, for $12,000 in “humanized mouse tissue procurement.”

Although the initial award was $12,000, the total estimated amount of funds allocated for the requisition was $60,000. In “Justification for other than full and open competition,” Obama’s FDA wrote:

“Scientists within the FDA and in the larger field of humanized mouse research have searched extensively over the past several years and ABR is the only company in the U.S. capable of supplying tissues suitable for HM [humanized mouse] research. No other company or organization is capable of fulfilling the need,” Life Site News reported.

Costs are estimated [for fetal parts] at $230.00 per tissue. Therefore, a total of 21 shipments equals $11,655.

In Feb. 2020, Judicial Watch first uncovered hundreds of pages of National Institutes of Health (NIH) records showing that the agency paid thousands of dollars to a California-based company to purchase organs from aborted human babies to create “humanized mice” for HIV research.

In May 2021, this lawsuit uncovered FDA records showing that the agency spent tens of thousands of taxpayer dollars to purchase human fetal tissue from ABR. The tissue was used to create “humanized mice” to test “biologic pharmaceuticals.”

On Aug. 3, 2021, Judicial Watch announced that this conservative organization and the Center for Medical Progress (CMP) received 252 pages of new documents from the U.S. Department of Health and Human Services through a separate lawsuit.

These documents revealed that nearly $3 million in federal funds were spent on research at the University of Pittsburgh to turn it into a “tissue center” for human fetal tissue from babies ranging from 6 to 42 weeks gestation.

Planned Parenthood supplies the fetuses to the University of Pittsburgh, which uses its access to fetal tissue to obtain NIH funding; in the end, the university sends payments and medical resources to Planned Parenthood, according to reports.

Humanized Mouse

Humanized Mouse (HM) is created by surgically implanting human tissue into rats and mice with multiple genetic mutations that block the development of the rodent’s immune system at a very early stage.

Scalps from aborted babies attached to the backs of mice as part of experiments carried out in the University of Pittsburgh. (nature.com)

The absence of the mouse immune system allows human tissues to grow into “functional human tissues.”

For “humanization” to proceed correctly, fetal tissue with a specific set of specialized characteristics is required.

On Sept. 24, 2018, under the Trump administration, the FDA terminated its contract with ABR to purchase human tissue and began an audit of its procurement of infant body parts.

Sign up to receive our latest news!

By submitting this form, I agree to the terms.